Shanetta D Ore

Array ( [id] => 11821870 [patent_doc_number] => 20170210807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR' [patent_app_type] => utility [patent_app_number] => 15/485159 [patent_app_country] => US [patent_app_date] => 2017-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 48561 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15485159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17541041 [patent_doc_number] => 11306152 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-19 [patent_title] => Anti-podoplanin antibody [patent_app_type] => utility [patent_app_number] => 16/498411 [patent_app_country] => US [patent_app_date] => 2017-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 10754 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18886360 [patent_doc_number] => 11865116 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Treatment of cancer with TG02 [patent_app_type] => utility [patent_app_number] => 16/087966 [patent_app_country] => US [patent_app_date] => 2017-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 27465 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16087966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17512603 [patent_doc_number] => 11291721 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-05 [patent_title] => Multispecific and multifunctional molecules and uses thereof [patent_app_type] => utility [patent_app_number] => 15/465564 [patent_app_country] => US [patent_app_date] => 2017-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 110 [patent_figures_cnt] => 110 [patent_no_of_words] => 98887 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15465564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11756072 [patent_doc_number] => 20170202939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'PERSONALIZED CANCER VACCINES AND METHODS THEREFOR' [patent_app_type] => utility [patent_app_number] => 15/458149 [patent_app_country] => US [patent_app_date] => 2017-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 34315 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15458149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16696736 [patent_doc_number] => 10947317 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => NaPi2b-targeted antibody-drug conjugates and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/457574 [patent_app_country] => US [patent_app_date] => 2017-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 44426 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 226 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15457574 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11895218 [patent_doc_number] => 09765143 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-19 [patent_title] => 'Methods for manipulating phagocytosis mediated by CD47' [patent_app_type] => utility [patent_app_number] => 15/456109 [patent_app_country] => US [patent_app_date] => 2017-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 105 [patent_no_of_words] => 34212 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15456109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11942125 [patent_doc_number] => 20170246276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'YEAST-BRACHYURY IMMUNOTHERAPEUTIC COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 15/454176 [patent_app_country] => US [patent_app_date] => 2017-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 32454 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15454176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13790759 [patent_doc_number] => 20190008918 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => IMMUNOMODULATION THERAPIES FOR CANCER [patent_app_type] => utility [patent_app_number] => 16/081144 [patent_app_country] => US [patent_app_date] => 2017-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16081144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13853925 [patent_doc_number] => 10188668 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-29 [patent_title] => Cancer drug and uses [patent_app_type] => utility [patent_app_number] => 15/451346 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 47689 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11704498 [patent_doc_number] => 20170172997 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'HISTONE DEACETYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/449151 [patent_app_country] => US [patent_app_date] => 2017-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 15358 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15449151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11948309 [patent_doc_number] => 20170252458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/448497 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 71815 [patent_no_of_claims] => 74 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15448497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14794037 [patent_doc_number] => 10400011 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-03 [patent_title] => Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers [patent_app_type] => utility [patent_app_number] => 15/445461 [patent_app_country] => US [patent_app_date] => 2017-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 37228 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15445461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16589321 [patent_doc_number] => 10898563 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Cancer immune-based therapy [patent_app_type] => utility [patent_app_number] => 15/445576 [patent_app_country] => US [patent_app_date] => 2017-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 20398 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15445576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383743 [patent_doc_number] => 20180243413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => Intralesional (Intratumoral) Dinitrochlorobenzene and Associated Compounds Coadministered with Checkpoint Inhibitors for Cancer Treatment Including Treatment of Metastatic Cutaneous Cancers [patent_app_type] => utility [patent_app_number] => 15/442615 [patent_app_country] => US [patent_app_date] => 2017-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5128 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15442615 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13095595 [patent_doc_number] => 10067134 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-04 [patent_title] => Diagnosis of benign and cancerous growths by measuring circulating tumor stem cells and serum AnnexinA2 [patent_app_type] => utility [patent_app_number] => 15/408886 [patent_app_country] => US [patent_app_date] => 2017-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 70 [patent_no_of_words] => 11193 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15408886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11836372 [patent_doc_number] => 20170218085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY' [patent_app_type] => utility [patent_app_number] => 15/403145 [patent_app_country] => US [patent_app_date] => 2017-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 87425 [patent_no_of_claims] => 56 [patent_no_of_ind_claims] => 37 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15403145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11604104 [patent_doc_number] => 20170121406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'STEM CELL ENHANCING THERAPEUTICS' [patent_app_type] => utility [patent_app_number] => 15/392858 [patent_app_country] => US [patent_app_date] => 2016-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 9575 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15392858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13533691 [patent_doc_number] => 20180318388 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => COMPOSITIONS AND METHODS FOR SENSITIZING LOW RESPONSIVE TUMMORS TO CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 15/749225 [patent_app_country] => US [patent_app_date] => 2016-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8033 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15749225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11864801 [patent_doc_number] => 20170232086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'CRYOPRESERVATION OF APOPTOTIC CANCER CELLS FOR USE IN IMMUNOTHERAPY AGAINST CANCER' [patent_app_type] => utility [patent_app_number] => 15/388972 [patent_app_country] => US [patent_app_date] => 2016-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 20219 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15388972 [rel_patent_id] =>[rel_patent_doc_number] =>)